Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10959845 | 1.00 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3728882 | 0.94 | LMNA (0.46) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28109752 | 0.92 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL11187859 | 0.92 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL9831013 | 0.88 | MEN1 (0.42) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13788522 | 0.84 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL7063128 | 0.83 | LMNA (0.42) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2617943 | 0.82 | LMNA (0.64) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2174100 | 0.82 | LMNA (0.64) | LMNACA12CA1CA2CA3 | |
| SCHEMBL7060257 | 0.82 | LMNA (0.41) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1094895-B1 | DOUBLE METAL CYANIDE CATALYSTS CONTAINING CYCLIC, BIDENTATE COMPLEXING AGENTS | BAYER ANTWERPEN NV (BE) | 2004-02-04 | — | — | EP | claimed |
| EP-1094895-A1 | DOUBLE METAL CYANIDE CATALYSTS CONTAINING CYCLIC, BIDENTATE COMPLEXING AGENTS | BAYER ANTWERPEN N.V. (BE) | 2001-05-02 | — | — | EP | claimed |
| US-6013596-A | A POLYETHER POLYMERIZATION CATALYST CONSISTS OF A DOUBLE METAL CYANIDE COMPOUND, AN ORGANIC COMPLEXING AGENT COMPRISING C3-C5 ALIPHATIC ALCOHOL AND CYCLIC, BIDENTATE LACTAM OR LACTONE COMPOUND | ARCO CHEMICAL TECHNOLOGY, L.P. (US) | 2000-01-11 | — | — | US | claimed |
| WO-1999059719-A1 | DOUBLE METAL CYANIDE CATALYSTS CONTAINING CYCLIC, BIDENTATE COMPLEXING AGENTS | BAYER ANTWERPEN N.V. (BE) | 1999-11-25 | — | — | WO | claimed |
| EP-0238088-A2 | Improved process for the preparation of dihydro-1H-pyrrolizine-3,5-(2H,6H)-dione | WARNER-LAMBERT COMPANY (US) | 1987-09-23 | — | — | EP | claimed |
| JP-53025557-A | — | — | None | — | — | JP | disclosed |
| US-20240132477-A1 | Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease | PFIZER INC. (US) | 2024-04-25 | — | — | US | disclosed |
| CN-110278711-B | Tricyclosulfones as rory modulators | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023218203-A1 | DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| CN-115724782-A | Preparation and removal method of levetiracetam impurities | 浙江华海药业股份有限公司 | 2023-03-03 | — | — | CN | disclosed |
| EP-3546940-B1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200103417-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON, INC. | 2020-04-02 | — | — | US | disclosed |
| WO-1999059719-A1 | DOUBLE METAL CYANIDE CATALYSTS CONTAINING CYCLIC, BIDENTATE COMPLEXING AGENTS | BAYER ANTWERPEN N.V. (BE) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999006397-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0885215-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030045-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | disclosed |
| EP-0238088-A2 | Improved process for the preparation of dihydro-1H-pyrrolizine-3,5-(2H,6H)-dione | WARNER-LAMBERT COMPANY (US) | 1987-09-23 | — | — | EP | disclosed |
| US-4543216-A | REACTING A VINYL BENZYL HALIDE WITH AN AMINO ACID OR AMINO SULFONIC ACID | NIPPON PAINT CO., LTD. (JP) | 1985-09-24 | — | — | US | disclosed |
| US-4452746-A | TO MODIFY PROPERTIES OF HIGH MOLECULAR WEIGHT COMPOUNDS | NIPPON PAINT CO., LTD. (JP) | 1984-06-05 | — | — | US | disclosed |
| JP-S5325557-A | OPTICAL ACTIVE LACTAMESTERS AND TREIR PREPARATION | TEIJIN LTD | 1978-03-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132477-A1 | Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease | ITK, BLK, BCKDK | LMNA 3439/4885CA12 4830/4885CA1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.